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ventional, none). RESULTS: Mean age of the sample (N = 1058)
was 38 years; 42% were male. The 6-month risk of discontinu-
ation was signiﬁcantly greater in patients with a Low vs. a High
initial dose (HR 0.74; 95% CI 0.58–0.94; P = 0.012) and trended
toward signiﬁcance when comparing a Medium vs. a High initial
dose (HR 0.86; 95% CI 0.69–1.10; P = NS). The largest differ-
ence in discontinuation rates between dose groups occurred after
the ﬁrst prescription. CONCLUSIONS: Patients initiating
ziprasidone therapy with an initial dose of at least 120mg/day
demonstrated better medication adherence compared with those
initiating at lower doses. This ﬁnding may reﬂect improved efﬁ-
cacy at daily doses ≥120mg.
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OBJECTIVES: To examine utilization of Emergency Depart-
ments (ED) for schizophrenia-related problems during a 1-year
period. METHODS: Data from 2001 and 2002 statewide 
Massachusetts ED and hospital databases were examined for
cases with a principal diagnosis of schizophrenia (ICD-9:
295.00–295.95). Cases where injury or non-related medical con-
ditions were coded were excluded. Data were examined for
demographics, visit status, arrival time, duration, disposition,
cost and repeat visits. Patients admitted were tracked by identi-
ﬁers in the hospital database. Cost estimates include accommo-
dations, ancillary and physician services, were adjusted for
national values and using 0.61 cost-to-charge ratio reported in
2004 in US$. RESULTS: Of 5686 cases identiﬁed, 72% were
male. Mean age was 46 years (range: 9–90). Visits were distrib-
uted evenly Monday through Friday, but decreased on weekends.
Almost half (48%) of all visits occurred between 3:00–11:00
PM. Visitation was coded as emergency for 57% of cases. Most
(46%) were admitted to acute hospitals, 22% transferred to
other facilities, 31% were treated and released from ED, 1% died
in ED or left AMA. Mean duration of ED visit was 5.3 hours
(median: 4.1). Mean cost per ED visit was $573 (median: $480)
for those released or transferred, and $366 for those admitted
(median: $329). In 2002, 45% of schizophrenia cases discharged
from Massachusetts acute hospitals came through ED. In one
year, 28% of those visiting an ED for a schizophrenia-related
problem had at least one other schizophrenia-related ED visit
(mean revisits: 2.1; range 1–22). Cumulative 1—year ED cost for
schizophrenia-related cases was roughly $2.6 million. CON-
CLUSIONS: The ED is a front line for schizophrenia manage-
ment, as it provides evaluation and referral services for
non-emergent patients, as well as acute treatment. Further
research is needed to determine if lack of availability, or access
to other mental health services prompted ED use.
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OBJECTIVES: To investigate utilization and persistence in
Zoloft patients versus those on other antidepressants.
METHODS: Using a 20% sample of California Medicaid claims
data from 1999 to 2003, patients on antidepressants were iden-
tiﬁed and tracked for 12 months from the ﬁrst ﬁll date of an anti-
depressant medication. Utilization patterns (discontinuation,
gap, switch, and augmentation events), medication possession
ratio (MPR), days covered (DC), and persistency (proportion of
patients on initial medication at least 80% of the time) were ana-
lyzed. Differences were tested using normal approximation with
a 2-sample test. Odds ratios were computed with respect to
Zoloft and tested using logistic regression models with propen-
sity scores. RESULTS: A total of 1403 patients were initiated on
Celexa, 1309 on Effexor, 10,758 on Paxil, 4631 on Prozac, and
2429 on Zoloft. Proportionally, more Zoloft patients were event-
free than Effexor or Paxil patients (p < 0.05), but less so than
Celexa. Adjusted odds ratios suggest that patients initiated on
Zoloft were more likely to persist with their medication than
patients on Effexor, Paxil or Prozac (OR = 0.824, 0.732, 0.762,
respectively; p < 0.05). Differences between Zoloft and Celexa
(OR = 1.040) were not statistically signiﬁcant. Zoloft had a
higher average MPR than Effexor, Paxil or Prozac, but slightly
lower than Celexa (p = 0.0259). All cohorts experienced a
decline in days covered (DC) on Day 31, 61, 91, and 181. At the
end of follow-up, 29.6% of patients initiated on Zoloft were still
taking the medication, which was signiﬁcantly higher than
patients on Effexor (24.3%), Paxil (24.9%) or Prozac (23.7%),
but slightly lower than patients on Celexa (32.6%, p = 0.0502).
CONCLUSIONS: Patients initiated on SSRI’s continue to have
relatively fast declines in medication adherence and persistence
within the recommended timeline for therapy.
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OBJECTIVES: 1) To characterize the design of drug beneﬁts of
SSRI antidepressants in health plans offered by employers in the
United States, and 2) determine the effect of raising co-payments
on compliance rates of SSRI antidepressants. METHODS: Data
comprised beneﬁt information and claims from Medstat’s Mar-
ketScan database for 2000–2003. Beneﬁt information was com-
piled from approximately 135 different plans. Any patient who
ﬁlled a prescription for an SSRI antidepressant in 2000 and was
continuously enrolled through 2001 was identiﬁed. A difference
in difference approach was used to examine the change in the
days supplied and number of claims ﬁlled for an employer that
raised their 3 tiered co-payments as compared to an employer
that kept constant one tier co-payment rates. RESULTS: Three
tier copayment structures were increasingly common among
employers. Most SSRI’s fall in tier 2 although some of the newer
SSRI’s are commonly found in tier 3. The average co-payment
for tier 1 increased from $5.40 to $7.40. The average co-
payment for tier 2 increased from $13.60 to $16.80. The average
co-payment for tier 3 increased from $25.40 to $31.20. When
the study employer raised their copayments by 50%, they expe-
rienced a 25% decline in the number of prescriptions per person
ﬁlled (from 5.2 to 3.9 prescriptions) from 2000 to 2001, while
the control employer demonstrated a 20% decline (from 6.0 to
4.8) in the number of prescriptions ﬁlled. Days supplied fell by
41.3 days or 24% in the employer that raised copayments and
by 36.3 days or 17% in the control employer. CONCLUSIONS:
Beneﬁt structure and co-payments have trended towards 3-tier
plans with increasing co-payments. As such, increasing co-
payments may have a negative effect on compliance and possi-
bly outcomes.
